title: Role of intestinal microbiota in transplantation outcomes.
abstract: While allogeneic hematopoietic stem cell transplantations have a curative potential, infections and graft-versus-host disease remain significant problems. The intestinal microbiota can influence responses to cancer chemotherapy and the role of the microbiota in affecting allogeneic hematopoietic stem cell transplantation outcomes is increasingly appreciated. The following paper discusses the most recent developments in this area.
authors.affiliation: Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York.
authors.forename: Ying
authors.initials: Y
authors.lastname: Taur
authors.affiliation: Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York.
authors.forename: Robert R
authors.initials: RR
authors.lastname: Jenq
authors.affiliation: Centro Superior de Investigacion en Salud Publica-FISABIO, Valencia, Spain.
authors.forename: Carles
authors.initials: C
authors.lastname: Ubeda
authors.affiliation: Division of Hematologic Oncology, Alan N. Houghton Chair, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York.
authors.forename: Marcel
authors.initials: M
authors.lastname: van den Brink
authors.affiliation: Weill Cornell Medical College, New York; Division of General Medicine, Chief, Infectious Diseases Service, Enid A. Haupt Chair in Clinical Investigation, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: pamere@mskcc.org.
authors.forename: Eric G
authors.initials: EG
authors.lastname: Pamer
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology / Q000401:mortality; D002986:Clinical Trials as Topic; D000069196:Gastrointestinal Microbiome; D006086:Graft vs Host Disease / Q000382:microbiology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D019337:Hematologic Neoplasms / Q000382:microbiology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality*; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage / Q000009:adverse effects; D009894:Opportunistic Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology / Q000401:mortality; D012307:Risk Factors; D016019:Survival Analysis; D014640:Vancomycin / Q000008:administration & dosage / Q000009:adverse effects; D065507:Vancomycin-Resistant Enterococci / Q000254:growth & development / Q000472:pathogenicity
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D008795:Metronidazole; D014640:Vancomycin
keywords: Allo-HSCT; Bacteremia; Diversity; Intestinal microbiota; Metronidazole; Microbial dominance; Mortality; Survival